Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 201–300 of 1,003
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bulic, B., Pickhardt, M., & Mandelkow, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 114
Hsp70 Protein Complexes as Drug Targets
Assimon, V. A., Gillies, A. T., Rauch, J. N., & Gestwicki, J. E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804143699 · Cited by 128
“The challenge of this strategy is that it has been notoriously difficult to target protein-protein interactions [22-24], such as those between Hsp70 and its co-chaperones.”
BackgroundSurvey of the year 2004 commercial optical biosensor literature
Rich, R., & Myszka, D. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.753 · Cited by 221
“Plot of equilibrium dissociation rate constants determined for a variety of biological systems (denoted by the different symbols) by both SPR and analytical centrifugation (blue [1,237,244,846]), isothermal calorimetry (green [194,200, 280,64,534,542]), fluorescence (red [188,280,413,830]), NMR (pink [844]), or KinExA…”
BackgroundA Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
p53-A natural cancer killer: Structural insights and therapeutic concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 93
Villoutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C., Lagorce, D., Sperandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 116
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges
Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 112
“Indeed, pharmacological inhibition of protein– protein interaction has proved challenging over the years, particularly with regard to achieving required selectivity and potency [130].”
BackgroundPeptide and peptoid foldamers in medicinal chemistry
Horne, W. S. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.632002 · Cited by 113
“The invention of synthetic agents that disrupt protein--protein binding interactions has proven a significant challenge for small-molecule drug development [92].”
BackgroundInsights into Protein–Protein Interfaces using a Bayesian Network Prediction Method
Bradford, J. R., Needham, C. J., Bulpitt, A. J., & Westhead, D. R. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.07.028 · Cited by 115
“These results strongly suggest that our protein–protein interface method can help locate critical regions on a protein surface that can be targeted by drugs, especially in light of the recent evidence to suggest that small molecule inhibitors can make effective protein– protein interaction blockers.(1,2) We compared o…”
BackgroundResultFragment-based approaches to enzyme inhibition
Ciulli, A., & Abell, C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.003 · Cited by 109
“Fragments are now being used to address increasingly challenging targets, such as protein–protein interactions [53] and RNA [54].”
BackgroundBarile, E., & Pellecchia, M. (2014) · Chemical Reviews · doi:10.1021/cr500043b · Cited by 106
Christensen, N. R., Čalyševa, J., Fernandes, E. F. A., Lüchow, S., Clemmensen, L. S., Haugaard‐Kedström, L. M., & Strømgaard, K. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800143 · Cited by 123
Targeting EZH2 for cancer therapy: From current progress to novel strategies
Zeng, J., Zhang, J., Sun, Y. J., Wang, J., Ren, C., Banerjee, S., Ouyang, L., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114419 · Cited by 114
Lise, S., Archambeau, C., Pontil, M., & Jones, D. T. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-365 · Cited by 107
“Reliable hot spots predictions can therefore represent the first step in rational drug design projects [3,4].”
BackgroundA Chemical Inhibitor Reveals the Role of Raf Kinase Inhibitor Protein in Cell Migration
Zhu, S., Henry, K. T. M., Lane, W. S., & Fenteany, G. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.07.007 · Cited by 110
Thorsen, T. S., Madsen, K. L., Rebola, N., Rathje, M., Anggono, V., Bach, A., Moreira, I. S., Stuhr-Hansen, N., Dyhring, T., Peters, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902225107 · Cited by 108
“An attractive alternative would be to develop medicines that instead target protein–protein interactions in a specific intracellular signaltransduction pathway (4, 5).”
BackgroundSandanaraj, B. S., Vutukuri, D. R., Simard, J. M., Klaikherd, A., Hong, R., Rotello, V. M., & Thayumanavan, S. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051947+ · Cited by 107
Meireles, L. M. C., Domling, A. S., & Camacho, C. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq502 · Cited by 108
Huang, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.007 · Cited by 110
Rationally designed peptide regulators of protein kinase C
Churchill, E. N., Qvit, N., & Mochly‐Rosen, D. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.10.002 · Cited by 114
“However, protein-protein interactions constitute large surface interfaces of approximately 750-1500 Å in each partner, and structural studies of protein-protein pairs have not shown many small binding pockets that enable the fitting of small-molecule inhibitors [58].”
Ohoka, N., Morita, Y., Nagai, K., Shimokawa, K., Ujikawa, O., Fujimori, I., Ito, M., Hayase, Y., Okuhira, K., Shibata, N., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001091 · Cited by 103
“However, a limited number of pathogenic proteins are currently targeted by pharmacological inhibitors, primarily because many proteins do not have suitable binding pockets where a pharmacophore may interact to regulate protein activity (1,2).”
BackgroundInfluentialBojadzic, D., Alcazar, O., & Buchwald, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600372 · Cited by 113
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Burke, J. P., Bian, Z., Shaw, S., Zhao, B., Goodwin, C. M., Belmar, J., Browning, C. F., Vigil, D., Friberg, A., Camper, D. V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501984f · Cited by 98
Hashemi, Z. S., Zarei, M., Fath, M. K., Ganji, M., Farahani, M. S., Afsharnouri, F., Pourzardosht, N., Khalesi, B., Jahangiri, A., Rahbar, M. R., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.669431 · Cited by 108
Discovery of Small‐Molecule Interleukin‐2 Inhibitors from a DNA‐Encoded Chemical Library
Leimbacher, M., Zhang, Y., Mannocci, L., Stravs, M., Geppert, T., Scheuermann, J., Schneider, G., & Neri, D. (2012) · Chemistry – A European Journal · doi:10.1002/chem.201200952 · Cited by 100
Wang, Y., Strickland, C., Voigt, J. H., Kennedy, M. E., Beyer, B. M., Senior, M. M., Smith, E. M., Nechuta, T. L., Madison, V., Czarniecki, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901472u · Cited by 116
The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR–ABL
Hantschel, O., Grebien, F., & Superti-Furga, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1276 · Cited by 105
“Although protein–protein interfaces were considered to be undruggable until recently, the clinical use of the BH3-mimetic ABT-737 targeting Bcl-2 family members led investigators to reconsider this old dogma in drug discovery (49, 50).”
BackgroundA functional single-molecule binding assay via force spectroscopy
Cao, Y., Balamurali, M. M., Sharma, D., & Li, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705367104 · Cited by 103
Lafont, V., Schaefer, M., Stote, R. H., Altschuh, D., & Dejaegere, A. P. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21259 · Cited by 114
“However, the development of small molecules that modulate protein–protein interactions is difficult.(1) There are several examples of natural molecules that bind at protein interfaces(2) and a growing number of synthetic compounds that are aimed at perturbing protein–protein interactions (for a recent review,”
BackgroundDonsky, E., & Wolfson, H. J. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr498 · Cited by 102
Bach, A., Eildal, J. N. N., Stuhr‐Hansen, N., Deeskamp, R., Gottschalk, M., Pedersen, S. W., Kristensen, A. S., & Strømgaard, K. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1013924 · Cited by 112
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F.-E. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 92
Efficient Synthesis of a β-Peptide Combinatorial Library with Microwave Irradiation
Murray, J. K., Farooqi, B., Sadowsky, J., Scalf, M., Freund, W. A., Smith, L. M., Chen, J., & Gellman, S. H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja052733v · Cited by 103
Henchey, L. K., Porter, J. R., Ghosh, I., & Arora, P. S. (2010) · ChemBioChem · doi:10.1002/cbic.201000378 · Cited by 100
Arnold, L. A., Estébanez-Perpiñá, E., Togashi, M., Jouravel, N., Shelat, A., McReynolds, A. C., Mar, E., Nguyen, P., Baxter, J. D., Fletterick, R. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506693200 · Cited by 101
Allosteric inhibition through suppression of transient conformational states
Tzeng, S.-R., & Kalodimos, C. G. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1250 · Cited by 101
High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation
Crowe, A., Ballatore, C., Hyde, E. G., Trojanowski, J. Q., & Lee, V. M. ‐. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.056 · Cited by 110
Rational Development of β-Peptide Inhibitors of Human Cytomegalovirus Entry
English, E. P., Chumanov, R. S., Gellman, S. H., & Compton, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508485200 · Cited by 101
Nevola, L., Martín‐Quirós, A., Eckelt, K., Camarero, N., Tosi, S., Llobet, A., Giralt, E., & Gorostiza, P. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303324 · Cited by 115
Modulating apoptosis as a target for effective therapy
Fleischer, A., Ghadiri, A., Dessauge, F., Duhamel, M., Rebollo, M. P., Alvarez-Franco, F., & Rebollo, A. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.013 · Cited by 108
Comprehensive Peptidomimetic Libraries Targeting Protein–Protein Interactions
Whitby, L. R., & Boger, D. L. (2012) · Accounts of Chemical Research · doi:10.1021/ar300025n · Cited by 99
Keskin, O., Ma, B., Rogale, K., Gunasekaran, K., & Nussinov, R. (2005) · Physical Biology · doi:10.1088/1478-3975/2/2/s03 · Cited by 99
Supramolecular Nanofibers with Superior Bioactivity to Insulin-Like Growth Factor-I
Shang, Y., Zhi, D., Feng, G., Wang, Z., Mao, D., Guo, S., Liu, R., Liu, L., Zhang, S., Sun, S., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04406 · Cited by 99
Viaud, J., Zeghouf, M., Barelli, H., Zeeh, J.-C., Padilla, A., Guibert, B., Chardin, P., Royer, C. A., Cherfils, J., & Chavanieu, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700773104 · Cited by 98
Chang, L., Miyata, Y., Ung, P. M. U., Bertelsen, E. B., McQuade, T. J., Carlson, H. A., Zuiderweg, E. R. P., & Gestwicki, J. E. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.010 · Cited by 118
Axerio-Cilies, P., Lack, N. A., Nayana, M. R. S., Chan, K. H., Yeung, A., Leblanc, E., Guns, E. S. T., Rennie, P. S., & Cherkasov, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200532b · Cited by 97
Computational Prediction of Protein Hot Spot Residues
Kenneth Morrow, J., & Zhang, S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436412 · Cited by 98
Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers
Illendula, A., Gilmour, J., Grembecka, J., Tirumala, V. S. S., Boulton, A., Kuntimaddi, A., Schmidt, C., Wang, L., Pulikkan, J. A., Zong, H., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.032 · Cited by 99
Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 105
Ojida, A., Inoue, M.-A., Mito-oka, Y., Tsutsumi, H., Sada, K., & Hamachi, I. (2006) · Journal of the American Chemical Society · doi:10.1021/ja056585k · Cited by 102
Sivanesan, D., Beauchamp, C., Quinou, C., Lee, J., Lesage, S., Chemtob, S., Rioux, J. D., & Michnick, S. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.715870 · Cited by 108
Fundamental Link between Folding States and Functional States of Proteins
Kalbitzer, H. R., Spoerner, M., Ganser, P., Hozsa, C., & Kremer, W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja904314q · Cited by 96
Yeast chemical genomics and drug discovery: an update
Hoon, S. S., St.Onge, R. P., Giaever, G. N., & Nislow, C. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.07.006 · Cited by 110
Unleashing the power of p53: lessons from mice and men: Figure 1.
Poyurovsky, M. V., & Prives, C. (2006) · Genes & Development · doi:10.1101/gad.1397506 · Cited by 96
“In general, protein–protein interactions are viewed as poor targets for drug design due to the fact that protein complexes usually have large interacting surfaces not easily disturbed by small molecules (Arkin and Wells 2004).”
BackgroundSong, X., Chen, J., Zhao, M., Zhang, C., Yu, Y., Lonard, D. M., Chow, D., Palzkill, T. G., Xu, J., O’Malley, B. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604274113 · Cited by 97
“Biologics-based therapeutics, such as antibodies, exemplify success in PPI regulation (2).”
BackgroundInfluentialInhibitors and chemical probes for molecular chaperone networks
Gestwicki, J. E., & Shao, H. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.002813 · Cited by 97
“Together, these features seem, on the surface, to generate significant opportunities for probe development (30, 31).”
BackgroundNatural product-like chemical space: search for chemical dissectors of macromolecular interactions
Reayi, A., & Arya, P. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.04.007 · Cited by 95
Three-dimensional modeling of protein interactions and complexes is going ‘omics
Stein, A., Mosca, R., & Aloy, P. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.005 · Cited by 107
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
Bajwa, N., Liao, C., & Nikolovska-Coleska, Z. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.644274 · Cited by 91
“Despite the difficulties, successfully discovered small molecules that inhibit several PPIs have been reported [3,4].”
BackgroundSynthetic Self-Localizing Ligands That Control the Spatial Location of Proteins in Living Cells
Ishida, M., Watanabe, H., Takigawa, K., Kurishita, Y., Oki, C., Nakamura, A., Hamachi, I., & Tsukiji, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4046907 · Cited by 95
A credit-card library approach for disrupting protein–protein interactions
Xu, Y., Shi, J., Yamamoto, N., Moss, J. A., Vogt, P. K., & Janda, K. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.052 · Cited by 93
Fine-Tuning Multiprotein Complexes Using Small Molecules
Thompson, A. D., Dugan, A., Gestwicki, J. E., & Mapp, A. K. (2012) · ACS Chemical Biology · doi:10.1021/cb300255p · Cited by 92
“Also, it is relatively straightforward to envision how competitive inhibitors could block these interactions because the ΔG is contributed by a handful (typically less than 5) of tightly clustered residues (9, 38).”
BackgroundCell-Based Assay Design for High-Content Screening of Drug Candidates
Nierode, G. J., Kwon, P. S., Dordick, J. S., & Kwon, S. (2016) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1508.08007 · Cited by 108
“Thus, modulators of PPIs are attractive drug candidates [2, 112].”
BackgroundHomo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 100
Moretti, R., Fleishman, S. J., Agius, R., Torchala, M., Bates, P. A., Kastritis, P. L., Rodrigues, J. P. G. L. M., Trellet, M., Bonvin, A. M. J. J., Cui, M., et al. (2013) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24356 · Cited by 92
“4,5 A large number of computational methods have been developed to predict protein–protein binding affinity.”
MethodInvestigating Wnt signaling: a chemogenomic safari
McMillan, M., & Kahn, M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03613-5 · Cited by 96
Denis, C., Santos, J. S. O., Bureau, R., & Voisin‐Chiret, A. S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00983 · Cited by 99
Smith, A. J. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114562544 · Cited by 94
“Despite their clear potential for intracellular penetration, PPIs have proved to be challenging targets for SMs due to the large size and the flat geometry of the protein interaction interface, often with a lack of well-defined binding pockets.(70) Some progress has been facilitated by the identification of discrete b…”
BackgroundMunuganti, R. S. N., Leblanc, E., Axerio-Cilies, P., Labriere, C., Frewin, K., Singh, K., Hassona, M. D. H., Lack, N. A., Li, H., Ban, F., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3015712 · Cited by 88
Human monogenic disorders — a source of novel drug targets
Brinkman, R. R., Dubé, M., Rouleau, G. A., Orr, A. C., & Samuels, M. E. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1828 · Cited by 93
“Recently some of these types of interaction have begun to yield to informed chemical attac”
BackgroundChemical, Target, and Bioactive Properties of Allosteric Modulation
van Westen, G. J. P., Gaulton, A., & Overington, J. P. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003559 · Cited by 85
“can even be used to distort protein-protein interactions [24–26].”
BackgroundWillert, E. K., Fitzpatrick, R., & Phillips, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701111104 · Cited by 88
Wu, X., Luo, Q., & Liu, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02760-y · Cited by 99
“The speci fi c structure of MCL1 had rendered the design of speci fi c MCL1 inhibitors dif fi cult 94 .”
Facial Control of Nanoparticle Binding to Cytochrome c
Bayraktar, H., You, C., Rotello, V. M., & Knapp, M. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja067497i · Cited by 87
Drugging challenging targets using fragment-based approaches
Coyne, A. G., Scott, D. E., & Abell, C. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.010 · Cited by 86
Achary, P. G. R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200429102334 · Cited by 99
Strategien zur Modulation von Protein‐Protein‐Wechselwirkungen mit synthetischen Substanzen
Yin, H. H., & Hamilton, A. D. (2005) · Angewandte Chemie · doi:10.1002/ange.200461786 · Cited by 88
Distinct Binding Modes of Two Epitopes in Gab2 that Interact with the SH3C Domain of Grb2
Harkiolaki, M., Tsirka, T., Lewitzky, M., Simister, P. C., Joshi, D., Bird, L. E., Jones, E. Y., O’Reilly, N., & Feller, S. M. (2009) · Structure · doi:10.1016/j.str.2009.03.017 · Cited by 91
Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease
Waløen, K., Kleppe, R., Martínez, A., & Haavik, J. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272581 · Cited by 95
Inhibiting protein–protein interactions using designed molecules
Zhao, L., & Chmielewski, J. A. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.01.005 · Cited by 84
Computational Identification of Inhibitors of Protein-Protein Interactions
Zhong, S., Macias, A., & MacKerell, A. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318334 · Cited by 84
Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
Gonzalez, A. Z., Eksterowicz, J., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Duquette, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401767k · Cited by 84
Druggability of Intrinsically Disordered Proteins
Joshi, P., & Vendruscolo, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-20164-1_13 · Cited by 86
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 103
Bradshaw, R. T., Patel, B. H., Tate, E. W., Leatherbarrow, R. J., & Gould, I. R. (2011) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzq047 · Cited by 83
“…by ‘hot-spots’—residues or groups of residues which contribute disproportionately to the Gibbs free energy of binding, DG, and these hot-spots represent interesting targets for drug discovery (Arkin and Wells, 2004; Zhao and Chmielewski, 2005; Moreira et al., 2007a, b; Wells and McClendon, 2007).”
BackgroundGeng, C., Vangone, A., Folkers, G. E., Xue, L. C., & Bonvin, A. M. J. J. (2019) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.25630 · Cited by 82
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
Discovery of a novel small molecule binding site of human survivin
Wendt, M. D., Sun, C. C., Kunzer, A. R., Sauer, D. R., Sarris, K., Hoff, E. D., Yu, L. P., Nettesheim, D. G., Chen, J., Jin, S. S., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.042 · Cited by 82
Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 82
Jiang, L., Xie, C., Lung, H. L., Lo, K. W., Law, G., Mak, N. K., & Wong, K. (2018) · Theranostics · doi:10.7150/thno.26823 · Cited by 82
“Small-molecule or peptide inhibitors for proteins or protein-protein interactions have long been investigated with limited success [91-94].”
BackgroundHubert, P., Sawma, P., Duneau, J., Khao, J., Hénin, J., Bagnard, D., & Sturgis, J. N. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.2.12430 · Cited by 90
Petegem, F. V., Duderstadt, K. E., Clark, K. A., Wang, M. Y., & Minor, D. L. (2008) · Structure · doi:10.1016/j.str.2007.11.010 · Cited by 81
Shigdel, U. K., Lee, S.-J., Sowa, M. E., Bowman, B. R., Robison, K., Zhou, M., Pua, K. H., Stiles, D. T., Blodgett, J. A. V., Udwary, D. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006560117 · Cited by 80
Antibody-enabled small-molecule drug discovery
Lawson, A. D. G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3756 · Cited by 90
Whitby, L. R., Ando, Y., Setola, V., Vogt, P. K., Roth, B. L., & Boger, D. L. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201878v · Cited by 97
Reversible, Allosteric Small-Molecule Inhibitors of Regulator of G Protein Signaling Proteins
Blazer, L. L., Roman, D. L., Chung, A., Larsen, M. J., Greedy, B. M., Husbands, S. M., & Neubig, R. R. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065128 · Cited by 91
“There has been significant interest in developing small-molecule protein-protein interaction inhibitors (SMPPIIs) for use as research probes and potential therapeutic agents (Berg, 2003, 2008; Gadek and Nicholas, 2003; Arkin and Wells, 2004; Blazer and Neubig, 2009).”
BackgroundBalushi, A. A. A., & Gordon, R. (2014) · ACS Photonics · doi:10.1021/ph5000314 · Cited by 88
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.